Azanta A/S Announces Executive Management Change
Hellerup, Denmark, April 24, 2015.
Azanta announces that Executive Vice-President and CFO, Bo Kruse has chosen to resign to pursue new challenges outside Azanta. Lars Aaen, Chairman of the Board of Azanta A/S, has the following comments to the change: “I would like to thank Bo Kruse for his valuable contributions to Azanta’s development and I wish him good luck in the future”.
About Azanta A/S
Azanta A/S is a privately owned specialty pharma company primarily operating within oncology, women´s health and addiction medicine. The vision of Azanta A/S is to become an international market leader within specialty pharma products and innovative pharmaceutical products. Azanta A/S currently markets or makes available a string of specialty pharmaceutical products, including Nimoral, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy and Angusta for labor induction.
For further information, please visit www.azanta.com.
Hanne Damgaard Jensen – CEO
Tel: + 45 – 70 25 95 45
Fax: + 45 – 70 25 95 46